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Abstract
Background—Post-traumatic inflammation and excessive neutrophil activation cause multiple
organ dysfunction syndrome (MODS), a major cause of death among hemorrhagic shock patients.
Traditional resuscitation strategies may exacerbate inflammation and thus novel fluid treatments
are needed to reduce these post-traumatic complications. Hypertonic resuscitation fluids inhibit
inflammation and reduce MODS in animal models. Here we studied the anti-inflammatory
efficacy of hypertonic fluids in a controlled clinical trial.
Methods—Trauma patients in hypovolemic shock were resuscitated in a pre-hospital setting with
250 ml of either 7.5% hypertonic saline (HS; n=9), 7.5% hypertonic saline + 6% dextran-70
(HSD; n=8), or 0.9% normal saline (NS; n=17). Blood samples were collected on hospital
admission and 12 and 24 h post-resuscitation. Multi-color flow cytometry was used to quantify
neutrophil expression of cell-surface activation/adhesion (CD11b, CD62L, CD64) and
degranulation (CD63, CD66b, CD35) markers as well as oxidative burst activity. Circulating
concentrations of soluble intercellular adhesion molecule (sICAM)-1, vascular cell adhesion
molecule (sVCAM)-1, P-, E-selectins, myeloperoxidase (MPO), and matrix metallopeptidase
(MMP)-9 were assessed with immunoassays.
Results—MODS, leukocytosis, and mortality were lower in the HS and HSD groups than in the
NS group. However, these differences were not statistically significant. HS prevented priming and
activation and neutrophil oxidative burst and CD11b and CD66b expression. HS also reduced
circulating markers of neutrophil degranulation (MPO and MMP-9) and endothelial cell activation
(sICAM-1, cVCAM-1, sE-selectin, and sP-selectin). HSD was less capable than HS of
suppressing the upregulation of most of these activation markers.
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Conclusions—This study demonstrates that initial resuscitation with HS but neither NS nor
HSD can attenuate post-traumatic neutrophil and endothelial cell activation in hemorrhagic shock
patients. These data suggest that hypertonic resuscitation without dextran may inhibit post-
traumatic inflammation. However, despite this effect, neither HS nor HSD reduced MODS in
trauma patients with hemorrhagic shock.
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Introduction
Despite significant advances in injury prevention, pre-hospital resuscitation strategies,
damage control surgery and modern intensive care [1], trauma remains the fifth leading
cause of death among all age groups in the United States and the major cause of death
worldwide among persons under the age of 40 years [2]. Immediately after injury, the
amount of blood loss is a main determinant of outcome. In later stages, posttraumatic
hemorrhagic shock, initiated by massive tissue injury and ischemia/reperfusion, primes the
innate immune system for an exaggerated systemic inflammatory response syndrome (SIRS)
[3]. This process ultimately leads to multiple organ dysfunction syndrome (MODS), which
is the leading cause of death among those patients who die in the intensive care unit [4].
Moreover, conventional resuscitation strategies often exacerbate the underlying cellular
injury caused by hemorrhagic shock, and the type of fluid administered may play an
important role in the development of secondary injury.
The underlying pathogenesis of these related syndromes involves a complex cascade of
humoral and cellular activation events [5]. The mechanisms by which posttraumatic
hemorrhagic shock triggers SIRS and MODS have been extensively studied but not fully
understood. Excessive activation of neutrophils and endothelial cells results in upregulation
of cell surface adhesion molecules, including selectins and integrins, promoting adherence
of neutrophils to inflamed vascular endothelium. Resultant extravasation and sequestration
of neutrophils into vital organs with subsequent degranulation and release of protease and
other hydrolytic enzymes, liberation of reactive oxygen species, and the synthesis of
inflammatory cytokines are crucial steps in the development of shock-mediated MODS [6].
In order to prevent these post-traumatic complications, various pharmacological approaches
have been considered as possible strategies to reduce post-traumatic inflammation [6].
Among these treatments, hypertonic resuscitation has attracted particular interest because
hypertonic fluids have been shown to reduce neutrophil activation and tissue injury in
preclinical trials [7].
Treatment of neutrophils with hypertonic fluids activates intracellular signaling pathways
that suppress cell activation processes through cAMP-mediated pathways [8, 9]. When
administered in vivo, hypertonic resuscitation fluids have been shown to possess powerful
anti-inflammatory properties that result in reduced secondary organ damage in various
animal models of trauma [10], hemorrhagic shock, and sepsis [11–14]. These promising
laboratory findings along with encouraging initial clinical trials have generated considerable
interest in hypertonic resuscitation fluids as potential immunomodulatory treatments for
trauma patients [15–17]. In addition to their pharmacological properties, small-volume
hypertonic resuscitation strategies have the added logistic advantage of conserving fluid
resources under far-forward battlefield conditions. Therefore, much effort has been devoted
to study the efficacy of hypertonic fluids as alternative resuscitation fluids for combat
casualty care. While initial studies demonstrated that hypertonic fluids have clear
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advantages over isotonic fluids, subsequent clinical trials have failed to convincingly
demonstrate survival benefits and improvements of post-traumatic morbidity [17].
During this period, our laboratories have made progress in our understanding of the
molecular mechanisms by which hypertonic fluids regulate neutrophil functions [9,12,18].
We found that hypertonic saline can inhibit neutrophil activation in vitro when clinically
relevant doses are administered before or during cell stimulation. However, we also found
that timing of hypertonic fluid treatment is critical to achieve this effect [19]. Hypertonic
saline added to previously stimulated or primed neutrophils enhanced degranulation and
increased the release of proteolytic enzymes including elastase, suggesting that delayed
hypertonic resuscitation could aggravate neutrophil-mediated organ damage [8]. Indeed, a
mouse hemorrhagic shock model has shown that administering hypertonic saline after the
infusion of isotonic fluids can exacerbate lung tissue damage [19]. Furthermore, previous
laboratory studies suggested that different resuscitation fluid formulations differentially
modulate neutrophil activation and cellular injury profiles ex vivo [20]. However, there have
been no human studies to date that have directly compared the immunomodulatory capacity
of hypertonic saline alone versus hypertonic saline admixed with dextran for post-traumatic
resuscitation. Thus, it has remained unclear whether undesirable effects of specific fluids
and/or delayed resuscitation could have a negative impact on clinical outcome.
The current study was designed as an a priori sub-group analysis within a larger multi-center
clinical trial, conducted in eleven trauma centers across North America to investigate the
efficacy of pre-hospital resuscitation of trauma patients with two commonly used hypertonic
resuscitation fluids: hypertonic saline (HS; 7.5% NaCl) and hypertonic saline with dextran
(HSD; 7.5% NaCl + 6% dextran-70). The main focus of the parent trial was on determining
the effects of these fluids on patient survival, along with post-traumatic measures of organ
failure, infection, and sepsis. A detailed description of this trial can be found elsewhere [21].
In the present study, we evaluated neutrophil activation, adhesion, and degranulation
markers along with other inflammatory mediators in a smaller cohort of patients admitted to
two of the eleven trial centers. Our goal was to determine how pre-hospital treatment with
hypertonic fluids affects the post-traumatic inflammatory response after hemorrhagic shock.
Materials and Methods
Ethics Statement
This clinical study was conducted under the United States (US) regulations for Exception
from Informed Consent for Emergency Research (21 CFR 50.24) and the Canadian Tri-
Council Policy Statement: Ethical Conduct for Research Involving Humans in Emergency
Health Situations (Article 2.8). The protocol was reviewed and approved by the US Food
and Drug Administration and Canadian Institute for Health Research. The protocol was also
approved by all participating Institutional Review Boards (US) and Research Ethics Boards
(Canada), as previously described [21]. Blood samples were drawn from healthy volunteers
(controls) after obtaining written informed consent in accordance with the principles of the
Declaration of Helsinki and with the approval of the institutional review boards of the
participating hospitals in Washington, Toronto, and Boston.
Clinical trail
Study Design and Setting—This prospective experimental study was conducted as an a
priori subgroup analysis as part of a larger randomized, placebo-controlled, double-blinded
trial under the Resuscitation Outcomes Consortium (ROC) — a multicenter clinical trials
network designed to conduct interventional studies in the pre-hospital setting following life-
threatening trauma [21].
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Study Participants—For the current study, we included 34 shock patients that included
patients with a pre-hospital systolic blood pressure (SBP) of ≤70 mmHg and patients that
had a SBP between 71 and 90 mmHg as well as a concomitant heart rate ≥108 beats per min.
These enrollment criteria were chosen based on the rationale delineated previously [21].
Patients were excluded if they were <15 years of age, pregnant, or if they received
intravenous fluid therapy in the field (>2,000 ml of isotonic crystalloid fluids, any colloids,
or any blood products) prior to treatment with study fluids. In addition to study fluid (250
ml), the additional fluid volume administered en rout to the emergency department was
<1,000 ml. Excessive delay in treatment was another reason for exclusion, i.e., if the time
interval between call received for dispatch and study intervention was >4 h, patients were
excluded. Other exclusion criteria were pre-hospital cardiopulmonary resuscitation, severe
hypothermia (body core temperature <28°C), drowning or asphyxia due to hanging, burns
>20% total body surface area, isolated penetrating head injury, inability to obtain
intravenous access, or if a potential subject was known to be a prisoner. A group of twenty
asymptomatic adult donors served as a healthy control group.
Interventions—As previously reported [21], the randomized, placebo-controlled, double-
blinded three-arm trial compared the effects of a 250-ml bolus infusion of hypertonic saline
versus hypertonic saline with dextran versus normal saline as the initial resuscitation fluids
given to injured patients assessed to be in hemorrhagic shock. All study fluids used for this
trial were purchased from BioPhausia Inc., Stockholm, Sweden. The company provided
identical 250-ml infusion bags that contained either 7.5% NaCl combined with 6%
dextran-70 (HSD; RescueFlow), 7.5% NaCl without dextran (HS), or 0.9% NaCl (normal
saline, NS). These intravenous bags were distributed among the eleven different geographic
regions participating in this clinical trial of the ROC. Paramedics administered the treatment
solutions in a blinded fashion via intravenous access as the initial resuscitation fluid given
within 4 h of the incident. Once the study fluid had been administered, additional fluids
could be given as guided by local Emergency Medical Services protocols. Investigators
agreed to follow established guidelines for management of common conditions in the
critically ill trauma patient according to best practice guidelines as previously described
[21]. Clinical data collected upon hospital admission included age, gender, mechanism of
injury, and Injury Severity Score (ISS). The severity of illness was quantified using the
Multiple Organ Dysfunction Score (MODS) at the time of admission to the intensive care
unit (ICU). Additional clinical outcome parameters collected were the 28-day survival rate,
fluid and blood transfusion requirements, physiologic parameters, and evidence of
infections.
Blood samples—Two (Toronto and Seattle) of the eleven regional centers participating in
the parent ROC trial and the Beth Israel Deaconess Medical Center in Boston collaborated
in the substudy described in this report to assess cellular and soluble immuno-inflammatory
responses in patients treated with HS, HSD, or NS. IRB approvals to exchange patient
samples among the three institutions was obtained at each institution.
Serial samples of venous blood were collected into EDTA, sodium heparin and non-additive
Vacutainer® tubes (BD, Franklin Lakes, NJ, USA) at the time of admittance to the hospital
emergency department (within 3 hours of resuscitation) and subsequently at 12-, and 24-h
post-resuscitation. A single blood sample was obtained by venipuncture from each of 20
age-matched healthy volunteers. EDTA blood samples were used to assess routine clinical
laboratory values, including plasma sodium concentrations and leukocyte differential counts.
In addition, freshly drawn heparinized whole-blood was processed immediately to assess
neutrophil cell-surface activation, adhesion and degranulation markers, and circulating
concentrations of soluble endothelial adhesion molecules, MPO, and MMP-9 were
subsequently determined.
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Whole blood samples were used to analyze with flow cytometry the expression of specific
surface molecules that indicate various states of neutrophil activation. Neutrophil adhesion
was assessed with antibodies that recognize CD62L (L-selectin) and CD11b; while activated
cells express increased levels of CD11b on the cell surface they shed CD62L from the cell
surface. In addition to these adhesion markers, we also assessed markers of degranulation
using antibodies that recognize CD35, CD66b, and CD63. These degranulation markers are
present on the inner membranes of secretory vesicles (CD35), specific granules (CD66b),
and azurophilic granules (CD63). Neutrophil degranulation results in the fusion of these
vesicular membranes with the cell membrane and the expression of CD35, DC66b, and
CD63 on the cell surface. Freshly collected whole blood samples (100-μl) were placed in
12×75-mm polystyrene Falcon tubes and incubated for 20 min at room temperature in the
dark with saturating concentrations of CD66b-FITC, CD63-PE, CD14-PerCP, CD11b-APC,
CD64-FITC, CD35-PE, CD62L-APC antibody conjugates (BD Biosciences, San José, CA).
CD14 was assessed to facilitate separation of gated cell populations. Appropriate isotype-
matched antibodies were used in separate tubes to control for autofluorescence and non-
specific binding. After the incubation period, erythrocytes were removed by adding 2 ml of
FACS™ Lysing Solution (BD Biosciences) for 10 min followed by centrifugation at 500×g
for 5 min at room temperature. Cells were washed once with CellWASH™ (BD
Biosciences) and resuspended in 400 μl of a 1% paraformaldehyde solution. Stained cell
suspensions were acquired on a dual-laser FACSCalibur flow cytometer (BD Biosciences)
calibrated for four-color analysis using CaliBRITE™ beads (BD Biosciences). For each
sample, 103 neutrophils were acquired with CellQuest® software (BD Biosciences) using a
live-gate setting to distinguish the neutrophil population from other cells and debris
according to the CD14-PerCP fluorescence versus side-scatter (SSC) light characteristics.
Data analysis was performed with FlowJo software v.8.7 (Tree Star Inc., Ashland, OR).
Electronic analysis gates and quadrant markers were set to define positive and negative
populations using fluorescence histogram data according to the non-specific staining of
isotype-matched negative controls. Results were recorded as percentage (%)-positive cells
and mean channel fluorescence intensity (MFI; in arbitrary units, a.u.). Absolute cell counts
were obtained by multiplying the corresponding percentages of cells derived from FACS
analysis by total leukocyte counts obtained with a hematology analyzer (Coulter Electronics,
Hialeah, FL).
Oxidative burst activity
The intracellular oxidative burst capacity (i.e., generation of superoxide and secondary
reactive oxygen species) of whole blood neutrophils was measured with flow cytometry,
using commercially available fluorometric assay kits (PHAGOBURSTR® kit, Orpegen
Pharma, Heidelberg, Germany). This test provides a quantitative assessment of burst activity
by measuring the percentage and fluorescence intensity (MFI, in the FL1 530-nm emission
channel) of cells that oxidize the fluorogenic substrate dihydrorhodamine (DHR)-123 to
green fluorescent rhodamine (Rho)-123 in the presence of hydrogen peroxide]. Briefly, three
100-μl aliquots of each heparinized whole blood sample were placed in separate test tubes
and combined with 20 μl of either wash buffer (as an unstimulated control), N-formyl-
methionyl-leucyl-phenylalanine (fMLP), or phorbol 12-myristate 13-acetate (PMA) at final
concentrations of 5 and 8.1 μM, respectively. Simultaneously, 20 μl of DHR-123 substrate
solution was added to each tube and then samples were incubated in a water bath at 37° for
20 min. In all cases, reactions were stopped by placing chilling tubes in an ice bath.
Erythrocytes were lysed by addition of 2 ml of BurstTest Lysing Solution for 10 min. After
centrifugation at 250 g for 5 min, the lysates were discarded and the remaining white cells
resuspended and incubated with anti-CD14-APC at room temp for 15 min. The cells were
then washed with 3 ml of Wash Solution and centrifuged at 250×g. Finally, 200 μl of and
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propidium iodide (PI) solution in PBS (200 μg/ml) was added to each sample on ice.
Samples were analyzed using a FACSCanto (BD Biosciences) flow cytometer within 30
min. Neutrophil populations were gated using a CD14-APC/SSC-defined gate; 10,000
neutrophil events were recorded for each sample. Data were analyzed in FlowJo™ software
v.8.7 (Tree Star) and the results are presented as the % Rho-123-positive neutrophils and as
Rho-123 MFI expressed as a percentage of the untimulated control sample.
Soluble endothelial adhesion molecules, myeloperoxidase, and matrix metallopeptidase 9
Plasma and serum samples were isolated and stored at −80°C until analysis. Serum
concentrations of soluble ICAM-1, VCAM-1, E-selectin, P-selectin were measured in
duplicate with commercially available enzyme-linked immunosorbent assay (ELISA) kits
according to the manufacturer’s protocols (Quantikine®, R&D systems Inc., Minneapolis,
MN) and read on an automated microplate photometer (EL340, BIO-TEK Instruments,
Winooski, VT). Plasma levels of myeloperoxidase (MPO) and matrix metallopeptidase 9
(MMP-9) were measured using ultra-sensitive electrochemiluminescence-based
immunoassay detection and analyzed on a Sector Imager 6000 system according to the
manufacturer’s instructions (Meso Scale Discovery, LLC, Gaithersburg, MD).
Statistical analyses
All data were expressed as mean ± SEM. Biomarker levels were treated as normally
distributed continuous variables. For statistical analyses, Student’s t test was used for
continuous variables and χ2 test was used for categorical predictor variables. The non-
parametric Mann-Whitney U test was used for continuous variables that were not normally
distributed. Serial comparisons (time × treatment) of biomarkers between treatment groups
and control group were made using repeated measures ANOVA with post-hoc Bonferroni/
Dunn testing. All analyses were two-tailed and p-values < 0.05 were considered statistically
significant.
Results
Hypertonic resuscitation does not improve clinical outcome
The current report summarizes our findings with a small subgroup of trauma patients of the
larger ROC trial [21]. In this subgroup of patients, we assessed a number of immunological
parameters to determine how hypertonic fluids affect the inflammatory response to trauma.
This subgroup included a total of 34 patients with hemorrhagic shock who were enrolled in
the ROC study sites in Seattle and Toronto. Of the 34 patients, 9 received 250 ml HS, 8
received an equal volume of HSD, and 17 patients received 250 ml of NS (Table 1). There
were no significant differences between these 3 treatment groups with regards to gender
distribution, age, type of injury, and injury severity scores (ISS). The average multiple organ
dysfunction score (MODS) of patients treated with NS was higher than those of the HS and
HSD groups, but these differences were not statistically significant. However, patients
treated with HS arrived in the emergency department with an average systolic blood
pressure that was significantly higher than in the other treatment groups (Table 1). All of the
patients treated with HSD or HS survived, while two patients in the NS group died within a
week after hospitalization. Interestingly, while the average systolic blood pressures in the
HS group was higher than in the HSD group, these differences could not be explained by
corresponding sodium levels. As expected, the average plasma sodium concentrations in
patients treated with HS and HSD were similar and significantly higher than in the NS group
with sodium levels ranging in the lower bracket of normal values for healthy adult controls.
Leukocyte and neutrophil counts in all patients were significantly elevated compared to age-
matched healthy controls (Fig. 1). While leukocyte and neutrophil counts generally
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decreased after admission, they remained significantly elevated above healthy control values
throughout the 24-h observation period. Total leukocyte counts did not differ among patient
groups. However, the initial neutrophil count in the HS group was significantly lower than
in the NS group.
HS inhibits trauma-induced neutrophil activation
As a measure of neutrophil activation, we assessed the expression of adhesion molecules
and degranulation markers on the cell surface of neutrophils in whole blood samples of
trauma patients. Neutrophil CD11b expression in the NS group was significantly
upregulated compared to values of healthy controls (Fig. 2A). CD11b expression in patients
treated with HS was significantly lower compared to the NS group. In fact, throughout the
observation period, values in the HS group did not differ from healthy controls. In the HSD
group, only initial CD11b values at admission were lower than in the NS group. While
neutrophil activation results in increased CD11b expression, L-selectin (CD62L) expression
decreases because of a process termed L-selecting shedding. In the HSD and NS groups, but
not the HS group, we found evidence of L-selectin shedding on admission with CD62L
expression levels that were significantly lower than in healthy controls (Fig. 2B).
Interestingly, in the patients treated with HSD, L selectin shedding was, most pronounced
with CD62L expression values remaining significantly lower compared to the NS group
(Table 2). Taken together with the CD11b expression data, these findings suggest a higher
degree of neutrophil activation in the HSD group compared to the HS group.
HS inhibits trauma-induced neutrophil degranulation
A hallmark of the inflammatory response leading to host tissue damage after trauma is
neutrophil degranulation, which is responsible for the release of proteolytic enzymes and
other cytotoxic mediators such as myeloperoxidase (MPO) that cause secondary host tissue
damage [22]. Neutrophils possess four discrete types of granules that contain specific sets of
cytotoxic mediators; and these granules are released in a hierarchical fashion by the
mobilization of secretory vesicles, the most easily mobilized granule type, followed by
gelatinous (tertiary), specific (secondary), and then azurophilic (primary) granules [22].
While exocytosis of these granules causes the release of luminal proteins into the
extracellular space, this process also results in the incorporation of granule membrane
proteins into the cell surface, which can be assessed by flow cytometry. Using antibodies
recognizing CD35, CD66b, and CD63, we assessed degranulation of secretory vesicles
(CD35), specific granules (CD66b), and azurophilic granules (CD63), respectively. At
admission to the emergency department, CD35 was upregulated in the NS but not in the HS
or HSD groups, suggesting that hypertonic resuscitation in the field attenuates degranulation
of secretory vesicles (Fig. 2C). However, over the course of the subsequent 24-h observation
period, CD35 expression increased in all treatment groups to levels that were significantly
higher than in healthy controls. This indicates that the initial inhibition of this degranulation
process is relatively short-lived.
While both hypertonic fluids prevented initial CD35 expression, only HS reduced
upregulation of CD66b, which suggests that HS may be more effective than HSD in
preventing degranulation of specific granules (Fig. 2F). Neutrophil CD63 expression is a
measure of exocytosis of elastase-containing azurophilic granules. We found that CD63
expression in the HS and HSD groups was initially lower than in the NS group and in
healthy controls (Fig. 2D). One possible reason for this finding could be differential effects
on cell adherence and numbers of circulating CD63 positive neutrophils. This notion is
supported by the lower percentage of CD63 positive neutrophils in the HS and HSD groups
compared to the NS and control groups (Table 2).
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In addition to the degranulation markers described above, we also assessed the expression of
CD64 (Fcγ receptor I) on the cell surface of neutrophils. CD64 is a sensitive marker of cell
activation and bacterial infection [23]. Similar to our findings with CD66b, treatment with
HS but not with HSD attenuated the initial upregulation of CD64 seen on admission of
trauma patients (Fig. 2E). However, as with CD35 expression, these differences were
transient and CD64 expression increased over time in all treatment groups and reached
levels that were significantly higher than in controls within 12 h after admission. This trend
was paralleled by overall higher percentages of CD64 positive neutrophils in all patients
after admission to the hospital (Table 2).
Taken together these findings indicate that HS and, apparently to a lesser extent, HSD
treatment can inhibit trauma-induced neutrophil activation, suggesting that hypertonic fluid
resuscitation is indeed able to attenuate specific aspects of the inflammatory processes
involved in neutrophil activation.
HS abolishes neutrophil priming after trauma
In order to assess in more detail how the different resuscitation fluids affect neutrophil
activation, we measured oxidative burst of neutrophils in whole blood samples freshly
collected from trauma patients (Fig. 3). Heparinized whole blood samples were incubated
with or without fMLP or PMA and oxidative burst was assessed using flow cytometry. In
the NS group but also the HSD group fMLP-induced oxidative burst was significantly
higher than in the HS group reaching values ~4-times higher than in healthy controls. By
contrast, oxidative burst in the HS group was not different from that of healthy controls and
remained at these levels throughout the entire 24-h observation period. Stimulation of
control cells with PMA induced an oxidative burst response that was about 9-times higher
than the response elicited by fMLP. This response was further increased by trauma resulting
in ~6 fold higher levels in the NS and HSD groups. However, despite the powerful oxidative
burst response triggered by PMA, neutrophils of patients in the HS group showed a clearly
lower response compared to the HSD and NS groups. Taken together these data demonstrate
that trauma results in profound neutrophil priming that exacerbates oxidative burst in
response to subsequent stimuli such as fMLP or PMA. Importantly, we found that HS but
not HSD is able to attenuated neutrophil priming.
Evaluation of the proportion of rhodamine (Rho)-123 positive neutrophils revealed marked
differences between the three treatment groups (Table 3). On admission, which best reflects
the initial response to trauma and resuscitation, we found a significantly smaller percentage
of Rho-123 positive neutrophils in the HS group compared to the HSD and NS groups. This
was true for unstimulated cells as well as for cells stimulated with fMLP, indicting that HS
reduces cell activation as well as priming by trauma.
HS treatment reduces MPO and MMP-9 release
The findings described above indicated that HS treatment reduces neutrophil priming in
trauma patients. In order to study the effect of HS resuscitation on neutrophil activation in
more detail, we assessed concentrations of cytotoxic mediators released from neutrophils in
plasma samples of trauma patients treated with HS, HSD, or NS. Myeloperoxidase (MPO)
and matrix metallopeptidase (MMP)-9, also known as type IV collagenase or gelatinase B
are neutrophil proteases that are released from the azurophilic and gelatinous (tertiary)
granules, respectively [24]. MPO and MMP-9 concentrations in the plasma of trauma
patients were significantly higher than in healthy controls (Fig. 4). In the HS and HSD
groups, the initial MMP-9 levels at admission were significantly lower than in the NS group,
suggesting that both hypertonic resuscitation fluids can reduce the activation of neutrophils
in response to trauma. This was not observed in the case of MPO, where plasma levels at
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admission did not differ among the three treatment groups. In the HS group and, to a lesser
extent, in the HSD group, MPO and MMP-9 concentrations were below admission values 12
h after resuscitation. At this time point, MMP-9 values in the HS group were significantly
lower than in the HSD group. These findings suggest that the suppressive effect of HS on
MMP-9 release remains for at least 12 h after resuscitation. At the 24-h time point, MMP-9
levels increased again and did not differ among the three treatment groups, while MPO
concentrations at this time point were lower in the HS group than in the HSD group.
HS treatment reduces endothelial cell activation and damage
The results described above suggest that HS treatment reduces neutrophil activation.
Neutrophil activation and the sequestration of activated cells to host organs are critical steps
in the progression of MODS. Neutrophils are sequestered from the circulation by adhesion
molecules expressed on endothelial cells. Along with L-selectin, E- and P-selectins regulate
initial neutrophil rolling on the endothelial surface, while ICAM-1 and VCAM-1 induce
firm adhesion. These molecules are released from the endothelium in response to
inflammation and can thus serve as biomarkers of endothelial cell activation and/or damage
[25]. We found that trauma patients had significantly elevated levels of circulating
sICAM-1, sVCAM-1, sE-selectin, and sP-selectin levels over the 24-h observation period
after admission (Fig. 5). On admission, however, only sP-selectin levels were significantly
elevated compared to the concentrations found in healthy controls. While all patients
showed initially elevated sP-selectin levels on admission, these levels decreased in the HS
group and reached normal values within 12 h after admission. In contrast to sP-selectin, the
concentrations of the other three biomarkers increased over time after admission, suggesting
progressive endothelial activation and dysfunction. Interestingly, in the HS group but, these
increases were attenuated compared to the other two treatment groups. In fact, in the HS
group, sICAM-1, sVCAM-1, and sE-selectin levels remained at normal control levels
throughout the 24-h observation period. In the HSD group, however, plasma sICAM-1 and
sVCAM-1 concentrations at the 24-h time point were significantly higher than in the HS and
NS groups, suggesting more severe endothelial cell damage.
Discussion
The optimal dose, timing, and composition of intravenous fluids for resuscitation of
traumatic hemorrhagic shock patients remain controversial. Previous experimental and
clinical studies have shown that small-volume hypertonic/hyperoncotic resuscitation fluids
are effective intravascular volume expanders and attenuate post-traumatic inflammatory
cascades, as compared to conventional isotonic crystalloids. To our knowledge, this is the
first report to show that pre-hospital treatment with HS versus HSD differentially modulates
neutrophil and endothelial cell functions. We demonstrate that HS is more effective than
HSD in reducing post-traumatic alterations in cellular and soluble neutrophil and endothelial
cell activation marker profiles.
Hypertonic fluids have been shown to suppress neutrophil responses in vitro and to
ameliorate neutrophil-mediated host tissue damage in animal models of shock [10–14].
However, despite the generally encouraging results of the many laboratory studies that had
been performed with hypertonic fluids, clinical trials have yielded relatively unimpressive
results [17,26]. Based on previous work, we hypothesized that the reason for the
disappointing results of clinical trials may have been due to pro-inflammatory side effects
caused by delayed administration of hypertonic fluids. This hypothesis was based on
findings that hypertonic saline increases degranulation of neutrophils that were stimulated
with fMLP before being exposed to hypertonicity [8]. Moreover, it was shown that the
protective effect of hypertonic resuscitation in a mouse model of shock was lost or reversed
when hypertonic saline was administered after the infusion of isotonic fluids [27]. Based on
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the assumption that delayed treatment could have a negative impact on the clinical efficacy
of hypertonic resuscitation, we designed a clinical trial protocol that would reduce the
likelihood of such undesired side effects, namely by administering hypertonic fluids in a
pre-hospital setting before any other treatments.
A subsequent multicenter trial conducted by the ROC was based on this concept and has
allowed us to test the hypothesis that pre-hospital treatment with HS or HSD improves the
clinical efficacy of hypertonic fluid resuscitation. However, unfortunately this trial had to be
suspended prematurely on the basis of futility and potential safety concerns [21]. The Data
Safety Monitoring Board noted that mortality was higher in the HS and HSD groups
compared to the NS group. This was the case in the post randomization subgroup of patients
who did not receive any blood products in the first twenty-four hours. Detailed data analysis
indicated that this was due to an earlier mortality in the HS and HSD groups, but that there
were no differences in overall 28-day mortality between the treatment arms [21]. Despite the
early termination of the parent clinical trial, we were able to carry out the immunological
studies presented in this report using blood samples of patients who had been enrolled in the
Toronto and Seattle study sites. However, the resulting small sample size represents a
limitation of our current study.
Nevertheless, our findings suggest that hypertonic resuscitation can indeed reduce the
activation and priming of neutrophils. These results, thus, largely recapitulate previous
findings of preclinical laboratory studies. However, unexpectedly our study also revealed
marked differences between the HS and HSD treatment groups. This is somewhat
surprising, given that the mechanisms by which hypertonic fluids influence immune cells are
thought to depend primarily on osmotic effects, which were not markedly different between
the HS and HSD groups. Exposure of immune cells to hypertonic fluids has been shown to
result in rapid cell shrinkage that is accompanied by the release of cellular ATP;
extracellular ATP is converted to adenosine and adenosine suppresses neutrophils by
autocrine mechanisms that involve A2a adenosine receptors on the cell surface [9]. Since
both HS and HSD increased plasma sodium concentrations to comparable levels (Table 1), it
is unlikely that differences in the osmotic effects triggered by these fluids could explain the
divergent responses of neutrophils to these resuscitation fluids. Yet, we found remarkable
differences between the HSD and HS groups with regard to several post-traumatic
inflammatory responses we studied.
One possible explanation for these differences could be related to the synthetic colloid
dextran 70, which is the main distinction between HSD and HS. Dextran 70 may elicit an
inflammatory response that is negligible when administered in small quantities to healthy
subjects, but that might be amplified in severely traumatized patients by the
immunomodulatory effects of hypertonic saline. Although the effects of dextran 70 on the
induction of acute anaphylactoid and inflammatory reactions have been examined
previously [28], specific inflammatory responses to dextran 70 after traumatic and
hemorrhagic shock have not been well studied. However, some previous evidence supports
the notion that dextran can increase oxidative burst of neutrophils in vitro and the
transcription of inflammatory cytokines and chemokines, such as tumor necrosis factor-α
and interleukin-8 [29,30]. Dextrans are polysaccharides produced by lactic-acid bacteria
such as Leuconostoc mesenteroides. Special purification methods are required to isolate
dextran from culture media and to eliminate bacterial byproducts in order to obtain refined
dextran preparations suitable for clinical applications. While it may not be feasible to
quantitatively eliminate all trace contaminants and remaining culture byproducts are not
thought to cause dextran reactions, such byproducts could play at least a contributory role to
mild inflammatory responses that have been observed on rare occasions [30]. Previous in
vitro studies have shown that hypertonic saline at clinically relevant doses can enhance T
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cell responses by autocrine feedback mechanisms that involve ATP release and P2 receptor
activation [31–33]. Therefore, it is possible that dextran in combination with hypertonic
saline could exacerbate otherwise mild subclinical inflammatory responses, which could
explain why HSD was less effective than HS in suppressing some of the inflammatory
markers we studied.
However, despite the differences between HSD and HS we found in our substudy, the
overall results of the parent ROC trial indicate that there are no measureable differences in
clinical outcome between patients who received HSD or HS. This suggests that the
increased inflammatory markers we found in the HSD group may not affect the overall
clinical outcome in trauma patients. This notion is also supported by the fact that the HSD
and HS groups in our current substudy did not differ with regard to average MODS scores
(Table 1).
Over the last few years, we have found that osmotic cell shrinkage in response to HS
induces the release of intracellular ATP from many different cell types in addition to
neutrophils. Because all these different cell types express their own cell type-specific subsets
of the nineteen known ATP and adenosine receptors as well as members of the ecto-enzyme
families that metabolize released ATP, the responses of different cell types to HS likely vary
greatly. Extracellular ATP and autocrine signaling via these purinergic receptors are being
increasingly recognized as a general motif in immune cell activation [34]. Yet, little
information is currently available about how HS-induced ATP release affects immune cells
other than neutrophils and CD4+ T cells that we have studied in more detail in our previous
work. Moreover, the response of the endothelium to HS is poorly understood but likely to
have a major role in regulating neutrophil adhesion and sequestration to host organs. Thus, it
is possible that still unknown purinergic signaling events triggered by trauma and HS could
be reasons for the lack of clinical efficacy of HS resuscitation. As an example, we recently
found that trauma causes a dramatic increase in A3 adenosine receptor expression by
neutrophils [35]. A3 receptors have a co-stimulatory role in neutrophil activation by
counteracting the anti-inflammatory effect of A2a receptors [18]. Hence, increased A3
receptor expression in trauma patients may diminish the protective effects of HS [36].
In summary, our current study shows that pre-hospital resuscitation with HS, but not HSD,
suppresses markers of neutrophil and endothelial cell activation/damage as compared with
isotonic fluid. This study establishes, for the first time in trauma patients, that different
formulations of hypertonic resuscitation fluids differentially regulate various cellular and
molecular inflammatory pathways. Notwithstanding the lack of clinical utility observed in
the parent ROC multi-center trial [21], the specific immunomodulatory effects observed in
the patient cohorts studied here warrant further investigation of hypertonic resuscitation as a
means to dampen excessive post-traumatic inflammatory responses. However, the design of
effective hypertonic resuscitation strategies will require a detailed knowledge of how
hypertonic fluids influence purinergic signaling mechanisms and immune cell functions.
Acknowledgments
The Resuscitation Outcome Consortium is supported by a series of cooperative agreements with 10 regional clinical
centers and 1 data coordinating center (5U01 HL077863, HL077881, HL077871 HL077872, HL077866,
HL077908, HL077867, HL077885, HL077887, HL077873, HL077865) from the National Heart, Lung and Blood
Institute in partnership with the National Institute of Neurological Disorders and Stroke, US Army Medical
Research & Material Command; The Canadian Institutes of Health Research — Institute of Circulatory and
Respiratory Health; Defence Research and Development Canada, and the Heart and Stroke Foundation of Canada.
In addition, this work was funded in part by grants from the National Institutes of Health, GM-51477, GM-60475,
AI-072287, AI-080582, and the Congressionally Directed Medical Research Program PR043034.
Junger et al. Page 11














1. Duchesne JC, Barbeau JM, Islam TM, Wahl G, Greiffenstein P, et al. Damage control resuscitation:
from emergency department to the operating room. Am Surg. 2011; 77:201–206. [PubMed:
21337881]
2. Davidson GH, Hamlat CA, Rivara FP, Koepsell TD, Jurkovich GJ, et al. Long-term survival of
adult trauma patients. JAMA. 2011; 305:1001–1007. [PubMed: 21386078]
3. Angele MK, Schneider CP, Chaudry IH. Bench-to-bedside review: latest results in hemorrhagic
shock. Crit Care. 2008; 12:218. [PubMed: 18638356]
4. Brattstrom O, Granath F, Rossi P, Oldner A. Early predictors of morbidity and mortality in trauma
patients treated in the intensive care unit. Acta Anaesthesiol Scand. 2010; 54:1007–1017. [PubMed:
20626360]
5. Tsukamoto T, Chanthaphavong RS, Pape HC. Current theories on the pathophysiology of multiple
organ failure after trauma. Injury. 2010; 41:21–26. [PubMed: 19729158]
6. Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. Intensive Care Med.
1995; 3:277–285. [PubMed: 7790621]
7. Angle N, Cabello-Passini R, Hoyt DB, Loomis WH, Shreve A, et al. Hypertonic saline infusion: can
it regulate human neutrophil function? Shock. 2000; 14:503–508. [PubMed: 11092681]
8. Junger WG, Hoyt DB, Davis RE, Herdon-Remelius C, Namiki S, et al. Hypertonicity regulates the
function of human neutrophils by modulating chemoattractant receptor signaling and activating
mitogen-activated protein kinase p38. J Clin Invest. 1998; 101:2768–2779. [PubMed: 9637711]
9. Chen Y, Shukla A, Namiki S, Insel PA, Junger WG. A putative osmoreceptor system that controls
neutrophil function through the release of ATP, its conversion to adenosine, and activation of A2
adenosine and P2 receptors. J Leukoc Biol. 2004; 76:245–253. [PubMed: 15107462]
10. Scarpelini S, Rhind SG, Tien H, Spencer Netto AC, et al. Effects of hypertonic saline on the
development of acute lung injury following traumatic shock. J Organ Dysfunction. 2008; 4:99–
105.
11. Angle N, Hoyt DB, Cabello-Passini R, Herdon-Remelius C, Loomis W, et al. Hypertonic saline
resuscitation reduces neutrophil margination by suppressing neutrophil L selectin expression. J
Trauma. 1998; 45:7–12. [PubMed: 9680004]
12. Rizoli SB, Kapus A, Fan J, Li YH, Marshall JC, et al. Immunomodulatory effects of hypertonic
resuscitation on the development of lung inflammation following hemorrhagic shock. J Immunol.
1998; 161:6288–6296. [PubMed: 9834118]
13. Rotstein OD. Novel strategies for immunomodulation after trauma: revisiting hypertonic saline as
a resuscitation strategy for hemorrhagic shock. J Trauma. 2000; 49:580–583. [PubMed: 11038073]
14. Shukla A, Hashiguchi N, Chen Y, Coimbra R, Hoyt DB, Junger WG. Osmotic regulation of cell
function and possible clinical applications. Shock. 2004; 21:391–400. [PubMed: 15087814]
15. Rizoli SB, Rhind SG, Shek PN, Inaba K, Filips D, et al. The immunomodulatory effects of
hypertonic saline resuscitation in patients sustaining traumatic hemorrhagic shock: a randomized,
controlled, double-blinded trial. Ann Surg. 2006; 243:47–57. [PubMed: 16371736]
16. Bulger EM, Cuschieri J, Warner K, Maier RV. Hypertonic resuscitation modulates the
inflammatory response in patients with traumatic hemorrhagic shock. Ann Surg. 2007; 245:635–
641. [PubMed: 17414614]
17. Tyagi R, Donaldson K, Loftus CM, Jallo J. Hypertonic saline: a clinical review. Neurosurg Rev.
2007; 30:277–289. [PubMed: 17574484]
18. Chen Y, Hashiguchi N, Yip L, Junger WG. Hypertonic saline enhances neutrophil elastase release
through activation of P2 and A3 receptors. Am J Physiol Cell Physiol. 2006; 290:C1051–C1059.
[PubMed: 16282197]
19. Murao Y, Hoyt DB, Loomis W, Namiki S, Patel N, et al. Does the timing of hypertonic saline
resuscitation affect its potential to prevent lung damage? Shock. 2000; 14:18–23. [PubMed:
10909888]
20. Gushchin V, Alam HB, Rhee P, Kirkpatrick JR, Koustova E. cDNA profiling in leukocytes
exposed to hypertonic resuscitation fluids. J Am Coll Surg. 2003; 197:426–432. [PubMed:
12946798]
Junger et al. Page 12













21. Bulger EM, May S, Kerby JD, Emerson S, Stiell IG, et al. Out-of-hospital hypertonic resuscitation
after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg. 2011;
253:431–441. [PubMed: 21178763]
22. Hager M, Cowland JB, Borregaard N. Neutrophil granules in health and disease. J Intern Med.
2010; 268:25–34. [PubMed: 20497300]
23. Livaditi O, Kotanidou A, Psarra A, Dimopoulou I, Sotiropoulou C, et al. Neutrophil CD64
expression and serum IL-8: sensitive early markers of severity and outcome in sepsis. Cytokine.
2007; 36:283–290. [PubMed: 17368039]
24. Lin TC, Li CY, Tsai CS, Ku CH, Wu CT, et al. Neutrophil-mediated secretion and activation of
matrix metalloproteinase-9 during cardiac surgery with cardiopulmonary bypass. Anesth Analg.
2005; 100:1554–1560. [PubMed: 15920174]
25. Boldt J, Muller M, Kuhn D, Linke LC, Hempelmann G. Circulating adhesion molecules in the
critically ill: a comparison between trauma and sepsis patients. Intensive Care Med. 1996; 22:122–
128. [PubMed: 8857119]
26. Bulger EM. 7.5% saline and 7.5% saline/6% dextran for hypovolemic shock. J Trauma. 2011; 70
(5 Suppl):S27–S29. [PubMed: 21666775]
27. Inoue Y, Chen Y, Pauzenberger R, Hirsh MI, Junger WG. Hypertonic saline up-regulates A3
adenosine receptor expression of activated neutrophils and increases acute lung injury after sepsis.
Crit Care Med. 2008; 36:2569–2575. [PubMed: 18679117]
28. Dubick MA, Bruttig SP, Wade CE. Issues of concern regarding the use of hypertonic/hyperoncotic
fluid resuscitation of hemorrhagic hypotension. Shock. 2006; 25:321–328. [PubMed: 16670632]
29. Rhee P, Wang D, Ruff P, Austin B, DeBraux S, et al. Human neutrophil activation and increased
adhesion by various resuscitation fluids. Crit Care Med. 2000; 28:74–78. [PubMed: 10667502]
30. Ljungström KG. Safety of dextran in relation to other colloids - Ten years experience with hapten
inhibition. Infusionsther Transfusionsmed. 1993; 20:206–210. [PubMed: 7508309]
31. Loomis WH, Namiki S, Ostrom RS, Insel PA, Junger WG. Hypertonic stress increases T cell
interleukin-2 expression through a mechanism that involves ATP release, P2 receptor, and p38
MAPK activation. J Biol Chem. 2003; 278:4590–4596. [PubMed: 12464620]
32. Yip L, Cheung CW, Corriden R, Chen Y, Insel PA, et al. Hypertonic stress regulates T-cell
function by the opposing actions of extracellular adenosine triphosphate and adenosine. Shock.
2007; 27:242–250. [PubMed: 17304104]
33. Woehrle T, Yip L, Manohar M, Sumi Y, Yao Y, et al. Hypertonic stress regulates T cell function
via pannexin-1 hemichannels and P2X receptors. J Leukoc Biol. 2010; 88:1181–1189. [PubMed:
20884646]
34. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011;
11:201–212. [PubMed: 21331080]
35. Bulger EM, Tower CM, Warner KJ, Garland T, Cuschieri J, et al. Increased neutrophil adenosine
a3 receptor expression is associated with hemorrhagic shock and injury severity in trauma patients.
Shock. 2011; 36:435–439. [PubMed: 21841534]
36. Inoue Y, Tanaka H, Sumi Y, Woehrle T, Chen Y, et al. A3 adenosine receptor inhibition improves
the efficacy of hypertonic saline resuscitation. Shock. 2011; 35:178–183. [PubMed: 20661181]
Junger et al. Page 13













Fig. 1. Leukocyte and neutrophil counts were significantly elevated in all trauma patients
Peripheral blood samples were collected in EDTA vacutainers from healthy controls (n=20)
and trauma patients resuscitated with NS (n=17), HSD (n=8), or HS (n=9) at the time of
emergency department admission (≤3 h post-resuscitation) and 12 and 24 h post-
resuscitation. Total leukocyte counts (A) and neutrophil (B; PMN) differential counts were
determined with a Beckman Coulter Hematology Analyzer. Statistics: aP < 0.05 vs. age-
matched healthy controls; bP < 0.05 vs. time-matched NS-treated patients; cP < 0.05 vs.
time-matched HS-treated patients, by ANOVA.
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Fig. 2. Neutrophil cell-surface activation, adhesion, and degranulation markers
Cell-surface expression of CD11b (A), CD62L (B), CD35 (C), CD63 (D), CD64 (E), and
CD66b (F) were assessed by multiparameter flow cytometry using freshly drawn
heparinized whole blood. Results were expressed as mean fluorescence intensity (MFI ±
SEM) in arbitrary units (a.u.). The corresponding percentage of receptor-positive cells is
shown in Table 2. Blood was sampled serially from patients resuscitated with normal saline
(NS; n=17), hypertonic saline-dextran (HSD; n=8), or hypertonic saline (HS; n=9) upon
hospital admission (ED ≤3 h) and 12 and 24 h after resuscitation. Blood samples from age
and gender matched healthy volunteers served as control (n=20). Statistical analyses: aP <
0.05 vs. age-matched healthy controls; bP < 0.05 vs. time-matched NS-treated patients; cP <
0.05 vs. time-matched HS-treated patients, by ANOVA.
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Fig. 3. Neutrophil oxidative burst activity
Neutrophil oxidative burst activity was measured by assessing intracellular rhodamine
(Rho)123 mean fluorescence intensity (MFI ± SEM) in arbitrary units (a.u.) of neutrophils in
whole-blood samples from healthy controls (n=20) and trauma patients resuscitated with NS
(n=17), HSD (n=8), or HS (n=9) at the time of emergency department admission (≤3 h post-
resuscitation) and 12 and 24 h after resuscitation. Samples were incubated at 37°C with N-
formyl-methionine- leucine-phenylalanine (fMLP, 5 μM) as a weak stimulus or with
phorbol 12-myristate 13-acetate (PMA, 8.1 μM) as a strong stimulus. Rho-123 MFI values
were expressed as a percentage of unstimulated control samples. Statistical analyses: §P <
0.05 vs. unstimulated control values; aP < 0.05 vs. age-matched healthy controls; bP < 0.05
vs. time-matched NS-treated patients; cP < 0.05 vs. time-matched HS-treated patients, by
ANOVA.
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Fig. 4. Circulating myeloperoxidase and matrix metallopeptidase 9 levels
Plasma concentrations of MPO and MMP-9 were determined in healthy controls (n=20) and
trauma patients resuscitated with NS (n=17), HSD (n=8), or HS (n=9) at the time of
emergency department admission (≤3 h post-resuscitation) and 12 and 24 h after
resuscitation, using electrochemiluminescence-based immunoassay detection methods.
Statistical analyses: data are shown as mean ± standard error mean (SEM); aP < 0.05 vs.
age-matched healthy controls; bP < 0.05 vs. time-matched NS-treated patients; cP < 0.05 vs.
time-matched HS-treated patients, by ANOVA.
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Fig. 5. Soluble endothelial adhesion molecules
Serum concentrations of soluble (s)ICAM-1 (A), sVCAM-1 (B), sE-selectin (C), and sP-
selectin (D) were determined in healthy controls (n=20) and trauma patients resuscitated
with NS (n=17), HSD (n=8), or HS (n=9) at the time of emergency department admission
(≤3 h post-resuscitation) and 12 and 24 h after resuscitation. Statistics: data are shown as
mean ± standard error mean (SEM); aP < 0.05 vs. age-matched healthy controls (n = 20); bP
< 0.05 vs. time-matched NS-treated patients; cP < 0.05 vs. time-matched HS-treated
patients, by ANOVA.
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Table 1
Patient demographics and clinical characteristics of patients treated with the three
different resuscitation strategies







 Sample size 34 9 8 17
 Sex, n (% male) 25 (73.5) 8 (88.9) 5 (62.5) 12 (70.6)
 Age, yrs (SD) a 43 ±20 44 ±23 43 ±18 42 ±21
Clinical Characteristics
 Admission SBP, mean (SD), mmHg 123 ±29 141 ±31b 126 ±25 112 ±27
 Admission plasma Na+ (mM) 142±1 148±1a,b 148±1a,b 137±2
 Type of injury, n (%)
  Blunt 29 (85.3) 8 (88.9) 7 (87.5) 14 (82.4)
  Penetrating 5 (14.7) 1 (11.1) 1 (12.5) 3 (17.6)
 ISS, mean (SD) b 22 ±12 24 ±17 21 ±9 21 ±11
 Worst MODS score, mean (SD) b 5.7 ±5.9 4.9 ±3.9 4.8 ±5.3 6.6 ±7.2
Abbreviations: HS, hypertonic saline; HSD, hypertonic saline plus dextran; NS, normal saline; ISS, Injury Severity Score; MODS, Multiple Organ
Dysfunction Score.
Statistics: Results are expressed as mean ± standard deviation (SD);
a
P < 0.05 vs. age-matched healthy controls (n = 20);
b
P < 0.05 vs. time-matched NS-treated patients; Mann-Whitney U-test.
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